Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BioNTech SE
Bristol-Myers Squibb
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Bristol-Myers Squibb
Daiichi Sankyo
Bristol-Myers Squibb
AbbVie
BicycleTx Limited
Hoffmann-La Roche
Second Affiliated Hospital of Nanchang University
Eikon Therapeutics
Regeneron Pharmaceuticals
Shanghai Henlius Biotech
Institut Curie
Bio-Thera Solutions
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shandong New Time Pharmaceutical Co., LTD
Semmelweis University
Leiden University Medical Center
Shengjing Hospital
Shanghai Shengdi Pharmaceutical Co., Ltd
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Canadian Cancer Trials Group
The Netherlands Cancer Institute
National Cancer Centre, Singapore
Fudan University
ERYtech Pharma
Roswell Park Cancer Institute
Taizhou Hanzhong biomedical co. LTD
The Netherlands Cancer Institute
Canadian Cancer Trials Group
M.D. Anderson Cancer Center
Celgene
Velindre NHS Trust
University Hospital, Bonn
Transgene
GBG Forschungs GmbH
Merck Sharp & Dohme LLC
Chinese PLA General Hospital
Mateon Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
Hamamatsu University
Charite University, Berlin, Germany